samplefor weight loss
98%+ · 5mg · Lyophilized
Bulk discount
3+ pcs
€56.05
−5%
5+ pcs
€53.10
−10%
10+ pcs
€50.15
−15%
Discount is applied automatically at checkout.
Enter your email and we'll notify you when it's back:
Free shipping over €49
This product is sold strictly for in lab conditions (in vitro) research purposes. Not approved for human consumption.
Verified above 98%
98%+ verified — most batches reach 99%+
Included
Independent analysis from accredited laboratories
EU Shipping
3-7 days across the EU (Bulgaria — 1-2 days)
Secure Payment
Cash on delivery
Tirzepatide
Dual GIP/GLP-1 Receptor Agonist | Weight Loss & Diabetes
In short
Dual agonist of GLP-1 and GIP receptors studied in clinical models for synergistic control of metabolism and body weight.
Best sellers
Education
Related resources
Ready-to-use starter kit
Tirzepatide is a synthetic peptide consisting of 39 amino acids, structurally based on the naturally occurring gastric inhibitory polypeptide (GIP). At the molecular level, it functions as a dual agonist that simultaneously binds to and activates both GIP and GLP-1 receptors. Scientists investigate this molecule in vitro and in animal models to observe its mechanisms related to cellular energy metabolism and insulin secretion. While tirzepatide is the active ingredient in prescription medications (such as Mounjaro® and Zepbound®), this specific research-grade product is strictly for laboratory use and is not a medicine.
Research reagent for laboratory use only. Not a medicine. For medical questions, consult a physician.
Scientific review
Written by
Калина Тодорова
Magister Pharmaciae, MSc Pharmacy
Reviewed by
Борис Маринов
MSc Biochemistry & Molecular Biology
Reviewed on
Tirzepatide is a revolutionary dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. FDA-approved for both type 2 diabetes management and chronic weight management, it has demonstrated unprecedented efficacy for weight loss and metabolic health optimization. Tirzepatide works by mimicking incretin hormones that regulate blood sugar, slow gastric emptying, and reduce appetite, offering superior results compared to single-mechanism GLP-1 agonists.
22.5% weight loss over 72 weeks at 15 mg (SURMOUNT-1, NEJM 2022) Twincretin: GLP-1 + GIP — 50% stronger than semaglutide 5x higher GIPR affinity vs GLP-1R Thermogenic activation in brown fat Improved skeletal muscle insulin sensitivity
Dual agonist of GIP and GLP-1 receptors, glucose-dependent insulin stimulation, gastric emptying delay, glucagon suppression, central satiety signaling through hypothalamic pathways
Clinical trials demonstrate 15-22% body weight reduction in non-diabetic obese individuals - superior to all existing weight loss medications including semaglutide
Comprehensive improvement in waist circumference, blood pressure, triglycerides, HDL cholesterol, and insulin resistance markers
Preferentially reduces visceral adipose tissue while preserving lean muscle mass when combined with resistance training and adequate protein
Dosing
The typical regimens you'll see in the published research - for reference when planning in vitro or in vivo experiments. Not medical advice.
Disclaimer
These are regimens discussed in the research literature, not medical advice. Consult a healthcare provider before use.
Timing
Any time of day, with or without food
[Calculator]
Change water and dose · results update in real time
from product
Visual indicator
Pull to mark 10
10marks
Standard insulin syringe 1 ml (100 marks)
Concentration
2.50mg/ml
Dose volume
0.100ml
U-100 units
10units
Doses per vial
20doses
Recommended needle
29G–30G / 1 ml insulin
Small volume — draw slowly; 30G works for finer precision
Cycle planner: vials for 12 weeks, cost, schedule
Opens full calculator
Results are reference values - for in vitro work. Verify against the published literature for the specific peptide.
[Step by step]
6 steps from a sealed vial to the injection. Plain language.
Peptide vial (5 mg), bacteriostatic water vial, 1 larger syringe (3-5 ml) for drawing water and 1 insulin (1 ml) for doses. Alcohol swabs for sanitizing the caps.
Wash your hands before starting.
Wipe the rubber cap of the water vial with an alcohol swab. Insert the needle, invert the vial and draw exactly 2 ml. Get the exact volume from the calculator.
Larger syringe = smaller error in volume.
Wipe the peptide vial cap. Tilt the vial 45° and release the water SLOWLY down the inner wall. Peptides are fragile — a direct stream onto the powder denatures them.
SLOWLY · DOWN THE WALL · NOT ONTO THE POWDER.
Hold the vial between both palms and swirl slowly. DO NOT shake or flip sharply — peptides break down under mechanical stress.
DON'T SHAKE. Like tea — not like a cocktail.
The powder should fully dissolve. The solution is clear, no visible particles. If cloudy or with sediment — discard (wrong water or bad batch).
Clear = OK. Cloudy = discard.
With the insulin syringe draw the exact marks from the calculator. Swab the skin (abdomen 5 cm around the navel, thigh, or buttock), pinch a fold, insert at 45-90° and inject slowly.
Rotate sites every injection to avoid lipohypertrophy.
Schedule
Any time of day, with or without food
Remove tirzepatide vial from refrigerator and allow to reach room temperature for 15-20 minutes to prevent condensation
Clean vial tops with alcohol wipes using circular motion from center outward, allow to air dry completely
Calculate appropriate reconstitution volume based on desired concentration using the calculator below
Draw calculated amount of bacteriostatic water into insulin syringe, ensuring no air bubbles
Insert needle into tirzepatide vial at 45-degree angle against the glass wall, NOT directly into powder
Slowly inject BAC water down the side of the vial - inject drop by drop to avoid foaming or protein degradation
Remove needle and gently swirl vial in circular motion - NEVER shake vigorously as this destroys the protein
Allow solution to sit for 2-3 minutes if any cloudiness persists, then swirl gently again until completely clear
Final solution should be completely clear and colorless - any persistent cloudiness indicates degradation
Label vial with reconstitution date and concentration, store in refrigerator at 2-8°C immediately
Use within 28 days of reconstitution, always use fresh needle for each injection, inspect for particles before use
Nausea
common·SURMOUNT-1
Diarrhea
common·SURMOUNT-1
Vomiting
common
Constipation
common
Injection-site reaction
uncommon
Pancreatitis
rare
Compatibility
The pairings below come from research literature and established biohacker stacking patterns. Click a card for the full reasoning - when the partner is in our catalog you'll see a direct order link too.
This is a literature overview, not medical advice. Pairs not listed are not proven safe - they simply lack enough published data.
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
SURMOUNT-2 T2DM Trial (2023)
938 adults with T2DM and obesity | 72-week duration
15mg dose achieved 15.7% weight loss with significant improvements in all cardiometabolic parameters
SURPASS-CVOT Cardiovascular Outcomes (2023)
12,785 T2DM patients | 3.5-year follow-up | Primary prevention study
26% reduction in major adverse cardiovascular events, establishing cardioprotective benefits
SURMOUNT-1 Phase 3 Trial (2022)
2,539 adults with obesity | 72-week study | Multiple dose levels
15mg weekly dose achieved 22.5% weight loss vs 2.4% placebo - largest weight loss seen in pharmaceutical trials
SURPASS Clinical Program (2021-2022)
Multiple Phase 3 trials | >13,000 T2DM patients | Head-to-head comparisons
Superior HbA1c reduction and weight loss compared to insulin, semaglutide, and all existing diabetes medications
for longevity
for sexual health
No reviews yet. Be the first.
Share your experience with this peptide. We publish after a short moderation.
